BMS pulls speedy Opdivo approval for liver cancer in US

Bristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for hepatocellular carcinoma, a common form of liver cancer,

Look out BMS, Cytokinetics has its eye on mavacamten's turf

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ma

The key to psoriasis innovation? Dispelling the shadow of th...

Keytruda beats Opdivo to first-line oesophageal cancer OK in...

Merck & Co's Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer therapy in the EU, ahead of Bristol-Myers Squibb's rival Opdivo, but BM

BMS re-joins Alzheimer's push, paying $80m for Prothena's ta...

Just a few days after Biogen abandoned its tau-targeting Alzheimer's disease candidate gosuranemab, Bristol-Myers Squibb has opted into a rival drug, paying $80 million for rights to Prothe

EU okays BMS' azacitidine pill for first-line maintenance of...

Bristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that has been mainstay of acute myeloid leukaemia (AML) therapy for more tha